A phase II study of nivolumab plus ipilimumab and androgen receptor antagonist bicalutamide to stimulate thymic T cell generation in HER2-negative metastatic breast cancer. Page D. SABCS Annual Meeting; 2023 December 7; San Antonio, TX.
Document Type
Presentation
Publication Date
12-7-2023
Keywords
oregon; chiles
Clinical Institute
Cancer
Department
Oncology
Recommended Citation
Page, David, "A phase II study of nivolumab plus ipilimumab and androgen receptor antagonist bicalutamide to stimulate thymic T cell generation in HER2-negative metastatic breast cancer. Page D. SABCS Annual Meeting; 2023 December 7; San Antonio, TX." (2023). Articles, Abstracts, and Reports. 8328.
https://digitalcommons.providence.org/publications/8328
